Physics:Deuruxolitinib
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C17H10D8N6 |
| Molar mass | 314.417 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata.[1] If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.[2]
Deuruxolitinib is a deuterated derivative of ruxolitinib.
References
- ↑ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; Roberts, Janet L.; McMichael, Amy et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. https://pubmed.ncbi.nlm.nih.gov/35364216/.
- ↑ Taylor, Nick Paul (2022-05-23). "Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial". https://www.fiercebiotech.com/biotech/chasing-lilly-and-pfizer-concerts-jak-inhibitor-hits-high-notes-phase-3-alopecia-trial.
 |  |
